Target type: molecularfunction
Catalysis of the hydrolysis of a peptide bond in an oligopeptide, i.e. a molecule containing a small number (2 to 20) of amino acid residues connected by peptide bonds. [GOC:mah, ISBN:0198506732]
Oligopeptidase activity refers to the enzymatic hydrolysis of peptide bonds within oligopeptides, which are short chains of amino acids. These enzymes play crucial roles in various biological processes, including protein turnover, signal transduction, and the regulation of cellular function. They can be broadly classified based on their substrate specificity, mechanism of action, and cellular location.
Oligopeptidases typically exhibit specificity for certain amino acid residues at the cleavage site, often targeting regions with specific sequence motifs. This specificity allows for the precise processing of proteins and peptides, ensuring the generation of functional fragments. The mechanism of action for oligopeptidases can involve different catalytic strategies, such as serine, cysteine, or metallopeptidase activity.
Serine oligopeptidases utilize a serine residue in their active site to facilitate the hydrolysis reaction. Cysteine oligopeptidases employ a cysteine residue as the catalytic nucleophile. Metallopeptidases, on the other hand, rely on a metal ion, such as zinc, to promote the cleavage process.
Oligopeptidases are found in diverse cellular compartments, including the cytoplasm, lysosomes, and extracellular matrix. Their cellular localization reflects their specific roles in different biological pathways. For instance, cytoplasmic oligopeptidases contribute to protein degradation, while lysosomal oligopeptidases participate in the degradation of cellular debris and misfolded proteins.
In conclusion, oligopeptidase activity is a fundamental enzymatic function involved in the breakdown of peptides into smaller fragments. The diverse mechanisms, substrate specificities, and cellular locations of these enzymes highlight their crucial roles in cellular homeostasis, protein processing, and signal transduction. Understanding the molecular function of oligopeptidases provides insights into the intricate network of protein metabolism and its implications for various biological processes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Prolyl endopeptidase | A prolyl endopeptidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P48147] | Homo sapiens (human) |
Neprilysin | A neprilysin that is encoded in the genome of human. [PRO:WCB, UniProtKB:P08473] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
berberine | alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound | antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker | |
thiorphan | Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms. | N-acyl-amino acid | |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
galantamine | Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils. | benzazepine alkaloid; benzazepine alkaloid fundamental parent; organic heterotetracyclic compound; tertiary amino compound | antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite |
jkl 1073a | 8-oxoberberine: structure given in first source | ||
Berberine chloride (TN) | organic molecular entity | ||
palmatine | burasaine: structure in first source | berberine alkaloid; organic heterotetracyclic compound | plant metabolite |
captopril | captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug. Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. | alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor |
baicalin | dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative | antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug | |
n-benzyloxycarbonylprolylprolinal | N-benzyloxycarbonylprolylprolinal: inhibitor of prolyl endopeptidase | ||
sq 28603 | SQ 28603: a selective neutral endopeptidase inhibitor | ||
kelatorphan | kelatorphan: inhibitor of enkephalin metabolism; structure given in first source | ||
(3-(n-hydroxy)carboxamido-2-benzylpropanoyl)glycine | |||
n-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide | N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide: fluorogenic substrate for post-proline cleaving enzyme | ||
2-(4-morpholinyl)-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-4H-1-benzopyran-4-one: an aminochromone; exhibits both antiproliferative and antichemotactic activity in vitro | ||
cgs 26303 | CGS 26303: a potent non-peptidic inhibitor of neutral endopeptidase capable of protecting atrial natriuretic peptide from enzymatic degradation; structure given in first source | ||
bb3497 | BB3497: peptide deformylase inhibitor; structure in first source | ||
boswellic acid | boswellic acid: ursane type; RN given refers to (3alpha,4beta)-isomer; active principle of salai guggal; see also record for salai guggal | triterpenoid | |
berbamine | bisbenzylisoquinoline alkaloid; isoquinolines | ||
aromoline | aromoline: from roots of Stephania cepharantha; structure given in first source | ||
obamegine | obamegine: RN given refers to cpd without isomeric designation | bisbenzylisoquinoline alkaloid; isoquinolines | |
candoxatrilat | candoxatrilat : A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure. candoxatrilat: USAN lists candoxatrilat (UK-73,967) with RN 123122-54-3 | ||
actinonin | actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure | ||
phosphoramidon | phosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis. phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure | deoxyaldohexose phosphate; dipeptide | bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor |
omapatrilat | omapatrilat: structure in first source | dipeptide | |
n-(n-(phenyl)butyryl-l-prolyl)pyrrolidine | N-(N-(phenyl)butyryl-L-prolyl)pyrrolidine: inhibits prolyl endopeptidase; structure given in first source | ||
sitagliptin | sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity. | triazolopyrazine; trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic |
thiorphan | |||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
rutin | Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders. | disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone | antioxidant; metabolite |
kaempferol | 7-hydroxyflavonol; flavonols; tetrahydroxyflavone | antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite | |
baicalein | trihydroxyflavone | angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger | |
3,7-dihydroxyflavone | 3,7-dihydroxyflavone: structure in first source 7-hydroxyflavonol : Any flavonol carrying a 7-hydroxy substituent. | hydroxyflavan | |
uk 81,252 | sampatrilat: structure in first source | ||
vildagliptin | amino acid amide | ||
talabostat | talabostat: an antineoplastic agent; structure in first source | ||
11-keto-boswellic acid | |||
cgs 35066 | CGS 35066: an endothelin-converting enzyme-1 inhibitor; structure in first source | ||
(2s,3as,7as)-1-(((r,r)-2-phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1h-indole | S 17092-1: structure in first source; inhibits proline endopeptidase | ||
linagliptin | linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. | aminopiperidine; quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
alanylpyrrolidine-boronic acid | |||
acetyl-11-ketoboswellic acid | acetyl-11-ketoboswellic acid: a 5-lipoxygenase inhibitor; structure given in first source | triterpenoid | |
kyp 2047 | |||
gosogliptin | amino acid amide | ||
beta-Elemonic acid | beta-elemonic acid: extracted from Boswellia carterii | triterpenoid | |
mk-3102 | pyrrolopyrazole | ||
quininib | quininib : A styrylquinoline that is trans-2-styrylquinoline in which the the phenyl group has been substituted at position 2 by a hydroxy group. It is an anti-angiogenic compound that exerts a dose-dependent antagonism of the cysteinyl leukotriene pathway, preferentially antagonising cysteinyl leukotriene receptor 1. The major species at pH 7.3 quininib: has antiangiogenic activity; structure in first source | phenols; styrylquinoline | angiogenesis inhibitor |